title: Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
abstract: Secondary hyperparathyroidism is a characteristic feature of chronic kidney disease, which develops early in the course of chronic kidney disease, often in a progressive way. It occurs as the renal function continues to decline and is encountered following a series of biochemical abnormalities, which are responsible for initiation and maintenance of increased parathyroid hormone (PTH) secretion. Several agents are used in the management of secondary hyperparathyroidism. Paricalcitol is a new generation selective vitamin D receptor activator that lowers PTH levels by exerting a less hypercalcaemic and hyperphosphataemic effect. In addition, there is emerging evidence of the benefit of paricalcitol in preventing intravascular calcification and proteinuria.
authors.affiliation: City Hospital, Birmingham, UK. fouad.albaaj@swbh.nhs.uk
authors.forename: Fouad
authors.initials: F
authors.lastname: Al-Baaj
authors.forename: Punit
authors.initials: P
authors.lastname: Yadav
authors.forename: Adriece
authors.initials: A
authors.lastname: Al-Rifai
mesh_terms: D004872:Ergocalciferols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy; D016019:Survival Analysis; D014815:Vitamins / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D004872:Ergocalciferols; D014815:Vitamins; C084656:paricalcitol